​

TScan Therapeutics (TCRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

TScan Therapeutics Revenue Highlights

Latest Revenue (Y)

$2.82M

0

Main Segment (Y)

Reportable Segment

TScan Therapeutics Revenue by Period

TScan Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$2.82M-86.62%
2023-12-31$21.05M55.52%
2022-12-31$13.54M33.47%
2021-12-31$10.14M834.65%
2020-12-31$1.08M100.00%
2019-12-31--

TScan Therapeutics generated $2.82M in revenue during NA 2024, up -86.62% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

TScan Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30--100.00%
2024-03-31$566.00K-92.15%
2023-12-31$7.21M85.52%
2023-09-30$3.89M23.48%
2023-06-30$3.15M-53.73%
2023-03-31$6.80M680200.00%
2022-12-31$1.00K-99.97%
2022-09-30$3.36M-17.09%
2022-06-30$4.06M34.26%
2022-03-31$3.02M5.85%
2021-12-31$2.85M18.33%
2021-09-30$2.41M-15.31%
2021-06-30$2.85M40.50%
2021-03-31$2.03M154.97%
2020-12-31$795.00K174.14%
2020-09-30$290.00K100.00%
2020-06-30-100.00%
2020-03-31--

TScan Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

TScan Therapeutics Revenue Breakdown

TScan Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reportable Segment$2.82M

TScan Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).

TScan Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals$709.95M$176.57M
DAWNDay One Biopharmaceuticals$131.16M$20.07M
ITOSiTeos Therapeutics$35.00M$35.00M
PRQRProQR Therapeutics$6.38M$4.48M
CUECue Biopharma$5.49M$3.34M
ARWRArrowhead Pharmaceuticals$3.55M$2.50M
TCRXTScan Therapeutics$2.82M-
XFORX4 Pharmaceuticals$2.56M$560.00K
CGTXCognition Therapeutics--
ANNXAnnexon--
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
TERNTerns Pharmaceuticals--
DRMADermata Therapeutics--

TCRX Revenue FAQ

What is TScan Therapeutics’s yearly revenue?

TScan Therapeutics's yearly revenue for 2024 was $2.82M, representing a decrease of -86.62% compared to 2023. The company's yearly revenue for 2023 was $21.05M, representing an increase of 55.52% compared to 2022. TCRX's yearly revenue for 2022 was $13.54M, representing an increase of 33.47% compared to 2021.

What is TScan Therapeutics’s quarterly revenue?

TScan Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $566K, a -92.15% decrease from the previous quarter (Q4 2023), and a -91.68% decrease year-over-year (Q1 2023). TCRX's quarterly revenue for Q4 2023 was $7.21M, a 85.52% increase from the previous quarter (Q3 2023), and a 721000.00% increase year-over-year (Q4 2022).

What is TScan Therapeutics’s revenue growth rate?

TScan Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -79.19%, and for the last 5 years (2020-2024) was 159.54%.

What are TScan Therapeutics’s revenue streams?

TScan Therapeutics's revenue streams in c 24 are Reportable Segment

What is TScan Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of TScan Therapeutics was Reportable Segment. This segment made a revenue of $2.82M, representing 100.00% of the company's total revenue.